Real-world findings show comparable outcomes in patients with renal dysfunction in advanced urothelial cancer, suggesting potential for broader treatment eligibility.
These real-world findings indicate that patients with CrCl <30 ml/min experienced outcomes comparable to those with higher renal function, providing important evidence in a population that is often excluded from clinical trials.
No takes yet. Share an insight, caveat, or question.
Litt et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: